Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms21082839 http://scihub22266oqcxt.onion/10.3390/ijms21082839 32325767!7215413!32325767     free     free     free       Int+J+Mol+Sci 2020 ; 21 (8): ä Nephropedia Template TP {{tp|p=32325767|t=2020. COVID-19 Drug Discovery Using Intensive Approaches |pdf=|usr=}}{{32325767}} gab.com Text COVID-19 Drug Discovery Using Intensive Approaches JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32325767 #FOAvip Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable. Twit Text FOAVip COVID-19 Drug Discovery Using Intensive Approaches ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32325767 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32325767 #FOAvip English Wikipedia <ref>{{Cite pmid|32325767}}</ref> COVID-19 Drug Discovery Using Intensive Approaches #MMPMID32325767 Asai A; Konno M; Ozaki M; Otsuka C; Vecchione A; Arai T; Kitagawa T; Ofusa K; Yabumoto M; Hirotsu T; Taniguchi M; Eguchi H; Doki Y; Ishii H Int J Mol Sci 2020[Apr]; 21 (8): ä PMID32325767show ga Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable. |*Antiviral Agents/chemistry/therapeutic use[MESH] |*Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |China[MESH] |Coronavirus Infections/*drug therapy[MESH] |Drug Discovery[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH]COVID-19 Drug Discovery Using Intensive Approaches (epmc).pdf DeepDyve Pubget Overpricing